Medicus Pharma Ltd. announced promising interim results from its SKNJCT-003 Phase 2 clinical study aimed at the non-invasive treatment of basal cell carcinoma (BCC) using the investigational product D ...
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance Patients treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback